CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Tryp Therapeutics Breaks New Grounds...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Tryp Therapeutics Breaks New Grounds...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

Mustang Bio Teams up with Mayo Clinic on Novel CAR T Technology

Life Sciences Review | Wednesday, August 18, 2021
Tweet

The agreement is for a novel technology that may be able to reshape the administration of chimeric antigen receptor engineered T cell (CAR T) therapies and potentially be used as an off-the-shelf therapy.


FREMONT, CA: Mustang Bio, a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases, recently announced that the firm has executed an exclusive license agreement with Mayo Clinic. The agreement is for a novel technology that may be able to reshape the administration of chimeric antigen receptor engineered T cell (CAR T) therapies and potentially be used as an off-the-shelf therapy.


The technology, invented by Larry R. Pease, Ph.D., primary investigator and former head of Mayo Clinic’s Center for Immunology and Immune Therapies, is a two-step strategy to administering CAR T treatment. First, a peptide is given to the patient to stimulate the proliferation of the patient’s own T cells. Following that, a viral CAR construct is administered directly into the patient’s lymph nodes. The viral design then infects the activated T cells, effectively forming CAR T cells in the patient in vivo. With successful implementation, an off-the-shelf solution might be developed without the requirement to identify and expand patient T cells ex vivo.


“We are excited by the possibilities that this novel technology has to offer given our ongoing development of CAR T cell therapies in hematologic and solid tumor cancers,” said Manuel Litchman, M.D., President and Chief Executive Officer of Mustang. “The potential use of this technology to facilitate how these treatments are delivered to patients can lead to earlier treatment post diagnosis, and using an off-the-shelf therapy may reduce the cost of care, all of which would help bring more innovative treatments to a broader base of patients in need.”


A preclinical proof-of-concept has been established, and Mayo Clinic will continue to develop this technology.


“The immune cells are activated in vivo using the natural methods employed by the body to deal with infection rather than the artificial activation used to manufacture traditional CAR T cells ex vivo,” said Dr. Pease. “This could potentially reduce the substantial toxicities that are characteristic of traditional CAR T therapy.”


Once a lead construct has been found, Mustang expects to submit an Investigational New Drug (IND) application for a multicenter Phase 1 clinical study. The technology mentioned in this release has a financial interest in Mayo Clinic and Dr. Pease. Any funds raised will go toward Mayo Clinic’s non-profit goal of patient care, teaching, and research.


Weekly Brief

loading
Top 10 Leading BioTech Solution Companies - 2021
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/mustang-bio-teams-up-with-mayo-clinic-on-novel-car-t-technology-nwid-509.html